Abbott Laboratories (ABT) FY2021 results: revenue $43.1 billion, up 24.5% on the year
Abbott Laboratories (ABT) reported revenue of $43.1 billion for fiscal 2021, the year ended 31 December 2021, up 24.5% on the year before. Net income was $7.1 billion, up 57.3%, and diluted earnings per share $3.94. The figures are the company's own, from the 10-K it filed with the SEC on 18 February 2022.
Revenue
$43.1 billion
+24.5% on the year
FY2014FY2021
Operating margin
19.6%
15.5% a year earlier
FY2014FY2021
Net income
$7.1 billion
+57.3% on the year
FY2014FY2021
Diluted EPS
$3.94
+57.6% on the year
FY2014FY2021
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
10,533
7,901
6,136
+33.3%
Capital expenditure
1,885
2,177
1,638
-13.4%
Free cash flow
8,648
5,724
4,498
+51.1%
Free cash flow margin
20.1%
16.5%
14.1%
Cash from investing
-2,008
-2,215
-1,815
Cash from financing
-5,494
-2,779
-4,289
Depreciation and amortisation
3,538
3,327
3,014
+6.3%
Share-based compensation
640
546
519
+17.2%
Buybacks
2,299
403
718
+470.5%
Dividends paid
3,202
2,560
2,270
+25.1%
Diluted shares, weighted
1,789m
1,786m
1,781m
+0.2%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
35,802
32,784
31,088
+9.2%
Non-controlling interest
222
219
213
+1.4%
Short-term borrowings
0.0
n/a
n/a
Debt
18,050
18,747
18,139
-3.7%
Operating lease liabilities
956
902
755
+6.0%
Other liabilities
20,166
19,896
17,692
+1.4%
Total liabilities and equity
75,196
72,548
67,887
+3.6%
Fixed assets
8,959
9,029
8,038
-0.8%
Goodwill
23,231
23,744
23,195
-2.2%
Intangible assets
12,739
14,784
17,025
-13.8%
Investments
1,266
1,131
1,163
+11.9%
Cash and equivalents
9,799
6,838
3,860
+43.3%
Receivables
6,487
6,414
5,425
+1.1%
Inventory
5,157
5,012
4,316
+2.9%
Other assets
7,558
5,596
4,865
+35.1%
Total assets
75,196
72,548
67,887
+3.6%
10-K for the year ended 31 December 2021, filed 18 February 2022: the filing.